Study finds tracking tools too challenging for elderly, those with multiple conditions

If providers want the elderly and those with chronic conditions to adopt mobile health tools, developers will need to make the tools more convenient and easier to use, according to a study published in the Journal of Medical Internet Research.

Researchers from Weill Cornell Medical College and Laval University in Quebec interviewed 22 patients with multiple chronic conditions and seven providers about health data tracking habits. The average age of the patients was 64, and they had an average of 3.5 conditions, including chronic pain, depression, heart disease and type 2 diabetes.

The study found that multiple chronic conditions disproportionately affect low-income and elderly patients and predicted that such populations would have a more difficult time using health IT tools, such as diet and exercise applications or blood glucose monitoring tools.

Four themes came to light from the interviews:

  • Patients' health data are not merely perceived as facts, but prompt positive and negative emotions;
  • Patients say physicians often trust their own data, including lab reports, more than patients' self-reported data;
  • Patients track data for many reasons; and
  • Tracking health data is perceived as work for many patients.

To make a "public health impact," the authors wrote, new technology must "clearly reduce patient inconvenience and burden." They also noted that consumer health IT developers should take steps to "reach an audience that is broader than technologically sophisticated early adopters."

 

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.